India to Nigeria: Rifampicin Export Trade Route

The India to Nigeria Rifampicin corridor is one of India's established pharmaceutical export routes, with 125 shipments documented worth a combined $252.7M USD. The route is dominated by LUPIN LIMITED, which alone accounts for roughly 98% of all export value, reflecting the consolidated nature of India's rifampicin manufacturing sector.

Across 12 active suppliers, the average shipment value stands at $2.0M USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 78% of all shipments, consistent with rifampicin's non-urgent bulk-order profile.

Shipment activity peaks during July–September, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 20.8%, placing it at rank #9 among India's top rifampicin export destinations globally.

On the import side, key buyers of Indian rifampicin in Nigeria include NATIONAL TUBERCULOSIS AND LEPROSY, DR LABARAN SHEHU, NATIONAL TUBERCULOSIS AND LEPROSY C and 11 others. NATIONAL TUBERCULOSIS AND LEPROSY is the single largest importer with 58 shipments valued at $248.7M USD.

India's rifampicin exports to Nigeria are driven primarily by a handful of large-scale manufacturers. LUPIN LIMITED with 47 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 12 active exporters signals a competitive but concentrated market — buyers in Nigeria benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — LUPIN LIMITED, SVIZERA LABS PRIVATE LIMITED, MACLEODS PHARMACEUTICALS LTD — together account for 100% of total trade value on this route. The average shipment value of $2.0M USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as stop tb cat i & iii patient kit-a (gdf)rifampicin 150mg+ isoniazide 75mg+ pyrazinamide 400mg+ ethambutol*** and stop tb cat i & iii patient kit-a (gdf)rifampicin 150mg+ isoniazide 75mg+pyrazinamide 400mg+ ethambutol***, suggesting that buyers in Nigeria tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, NATIONAL TUBERCULOSIS AND LEPROSY is the largest importer with 58 shipments worth $248.7M USD — representing 98% of all rifampicin imports from India on this route. A total of 14 buyers are active on this corridor.